Leptin

Overview

Leptin is a 167-amino acid protein hormone produced predominantly by white adipose tissue. Its name derives from the Greek "leptos" meaning thin, reflecting its discovery as the product of the ob (obese) gene — the mutation responsible for extreme obesity in the ob/ob mouse strain. Jeffrey Friedman's laboratory at Rockefeller University identified leptin through positional cloning in 1994, a discovery that fundamentally altered the understanding of body weight regulation by establishing that adipose tissue is not merely a passive energy depot but an active endocrine organ.

Leptin functions as the body's long-term energy status signal. Circulating leptin levels are proportional to total adipose tissue mass — more body fat produces more leptin. This signal is transmitted to the hypothalamus, where it suppresses appetite, increases energy expenditure, and modulates neuroendocrine function. The system evolved primarily as a starvation-detection mechanism: falling leptin levels during energy deficit trigger powerful adaptive responses including increased hunger, decreased metabolic rate, and suppression of reproductive function.

The initial discovery generated enormous enthusiasm for leptin as an obesity treatment. However, clinical reality proved more complex. While rare cases of congenital leptin deficiency respond dramatically to leptin replacement, common obesity is characterized by leptin resistance — elevated leptin levels to which the brain no longer responds adequately. This distinction between leptin deficiency and leptin resistance has been central to obesity research for the past three decades.

Structure

Leptin is a 167-amino acid protein with a four-helix bundle cytokine fold, structurally related to the class I cytokine family (including IL-6, IL-11, and CNTF):

• Molecular weight: ~16,000 g/mol (16 kDa)
• Gene: LEP (chromosome 7q31.3)
• Receptor: LEPR (leptin receptor, also called OB-R)
• CAS Number: 152146-26-4 (human recombinant)

Structural features:

• Four alpha-helical bundle — characteristic cytokine fold with helices A, B, C, and D
• Single disulfide bond — Cys96-Cys146, essential for proper folding and biological activity
• No glycosylation required for activity, though post-translational modifications occur
• Circulates in free and bound forms — bound to soluble leptin receptor (sOB-R), which modulates bioavailability

Mechanism of Action

Leptin Receptor Signaling

Leptin binds to the leptin receptor (LEPR/OB-R), a single-transmembrane domain receptor of the class I cytokine receptor family. Six splice variants exist (OB-Ra through OB-Rf), but only OB-Rb (the long form) contains the full intracellular domain required for signal transduction:

JAK-STAT pathway (primary):

• Leptin binding induces OB-Rb dimerization
• Janus kinase 2 (JAK2) is constitutively associated with OB-Rb and undergoes transphosphorylation
• JAK2 phosphorylates tyrosine residues on OB-Rb
• STAT3 is recruited, phosphorylated, dimerizes, and translocates to the nucleus
• STAT3 activates transcription of target genes including POMC (pro-opiomelanocortin) and suppresses AgRP/NPY expression

Additional signaling pathways:

• PI3K/Akt pathway — mediates acute effects on neuronal firing
• MAPK/ERK pathway — involved in cellular proliferation and differentiation
• AMPK inhibition — reduces hypothalamic AMPK activity, decreasing food intake

Hypothalamic Circuits

Leptin acts on two opposing neuronal populations in the arcuate nucleus:

Anorexigenic (appetite-suppressing):

• POMC/CART neurons — leptin activates these neurons, increasing production of alpha-MSH, which acts on MC4R to reduce food intake
• This connects leptin signaling directly to the melanocortin system

Orexigenic (appetite-stimulating):

• AgRP/NPY neurons — leptin inhibits these neurons, reducing production of the potent appetite stimulators AgRP and neuropeptide Y

Leptin Resistance

In common obesity, leptin resistance develops through multiple mechanisms:

• Impaired BBB transport — leptin crosses the blood-brain barrier via a saturable transport system; in obesity, transport capacity is overwhelmed
• SOCS3 upregulation — suppressor of cytokine signaling 3 is induced by leptin itself and acts as a negative feedback inhibitor of LEPR signaling
• PTP1B activation — protein tyrosine phosphatase 1B dephosphorylates JAK2, attenuating signaling
• Endoplasmic reticulum stress — ER stress in hypothalamic neurons impairs LEPR processing
• Inflammation — hypothalamic inflammation associated with high-fat diets impairs leptin signaling

Research Summary

Pharmacokinetics

• Half-life: Approximately 25 minutes (free form); longer effective half-life due to sOB-R binding
• Circulating levels: Proportional to fat mass; typically 5-15 ng/mL in lean individuals, 30-100+ ng/mL in obese individuals
• Diurnal variation: Pulsatile secretion with nocturnal peak (highest around 2 AM)
• Route: Subcutaneous injection (metreleptin)
• Metabolism: Renal clearance is the primary elimination route
• Sexual dimorphism: Women have 2-3x higher leptin levels than men at equivalent body fat percentages, attributed to estrogen effects and subcutaneous fat distribution

Clinical Application: Metreleptin

Metreleptin (brand name Myalept) is a recombinant methionyl human leptin analog approved by the FDA in 2014:

• Indication: Generalized lipodystrophy — patients who lack adipose tissue and therefore produce virtually no leptin
• Effect: Replaces the missing signal, dramatically reducing hyperphagia, hypertriglyceridemia, and insulin resistance
• REMS program: Restricted distribution due to theoretical risk of anti-leptin antibodies that could neutralize endogenous leptin
• Not approved for common obesity — leptin resistance limits efficacy in typical obese patients

Common Discussion Topics

1. Why leptin fails as an obesity drug — The distinction between leptin deficiency (rare, treatable) and leptin resistance (common, not easily treated with more leptin) is the central narrative of leptin biology. Giving more leptin to someone who is already leptin-resistant is analogous to treating type 2 diabetes purely by giving more insulin.

2. Post-diet leptin drop — When body fat decreases, leptin falls rapidly, triggering powerful compensatory mechanisms that drive weight regain. This "leptin gap" between reduced fat mass and the brain's expected leptin signal is a major contributor to the difficulty of maintaining weight loss.

3. Leptin and fertility — Leptin is a critical permissive signal for reproduction. Below a threshold leptin level, the hypothalamic-pituitary-gonadal axis is suppressed, which explains amenorrhea in extremely lean athletes and anorexia nervosa patients.

4. Adiponectin relationship — Unlike leptin, adiponectin levels are inversely correlated with fat mass. Together, leptin and adiponectin represent complementary adipokine signals with distinct metabolic effects.

5. Ghrelin counterregulation — Ghrelin and leptin function as opposing signals in energy balance — ghrelin promoting hunger and leptin promoting satiety — though the relationship is more nuanced than a simple seesaw.

Related Compounds

• Ghrelin — appetite-stimulating peptide that opposes many leptin actions
• Adiponectin — complementary adipokine with insulin-sensitizing effects
• Insulin — metabolic hormone with overlapping hypothalamic satiety signaling
• Neuropeptide Y — hypothalamic appetite stimulator suppressed by leptin
• Cholecystokinin — short-term satiety peptide from the gut
• Alpha-MSH — downstream melanocortin effector of leptin signaling